SecBot SecBot
SECBOTREPLAY Home › Report › TEVA

TEVA · The U.S

Teva Pharmaceuticals International Gmbh · COURT-RULING filed Apr 15, 2026 at 20:00 ET

At the news

BULLISHIMPACT 8/10

COURT-RULING filed Apr 15, 2026 at 20:00 ET

The U.S. Court of Appeals for the Federal Circuit reversed a lower court's judgment invalidating Teva's headache-related patents, reinstating a jury verdict that Eli Lilly willfully infringed the patents. This strengthens Teva's IP position and may lead to damages or licensing revenue.

  • Federal Circuit reversed lower court's invalidation of Teva's U.S. Patent Nos. 8,586,045, 9,884,907, and 9,884,908
  • Appellate court reinstated jury finding that Eli Lilly willfully infringed the patents
  • Ruling affirms validity of Teva's patents covering use of humanized anti-CGRP antagonist antibodies to treat headache
  • Case remanded for further proceedings consistent with the opinion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access